Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Codon Devices has entered into a research, development and licensing agreement with Merrimack Pharmaceuticals, to apply the company's proprietary BioLOGIC platform to the development of novel therapeutic proteins identified by Merrimack.
Subscribe to our email newsletter
Under the terms of the agreement, Codon will receive clinical milestone payments and royalties on net sales that may result from Merrimack’s development and commercialization of any protein product coming out of the collaboration.
Brian Baynes, president of Codon Devices, said: “This agreement reinforces the value of our BioLOGIC platform for the rapid development of superior proteins with desired properties in the important field of therapeutic products, in addition to other opportunities for enhanced products in next-generation biosecurity, improved agricultural products and engineered vaccines.”